110 related articles for article (PubMed ID: 22553815)
1. In silico analysis and immunohistochemical characterization of NaPi2b protein expression in ovarian carcinoma with monoclonal antibody Mx35.
Soares IC; Simões K; de Souza JE; Okamoto OK; Wakamatsu A; Tuma M; Ritter G; Alves VA
Appl Immunohistochem Mol Morphol; 2012 Mar; 20(2):165-72. PubMed ID: 22553815
[TBL] [Abstract][Full Text] [Related]
2. Monoclonal antibody MX35 detects the membrane transporter NaPi2b (SLC34A2) in human carcinomas.
Yin BW; Kiyamova R; Chua R; Caballero OL; Gout I; Gryshkova V; Bhaskaran N; Souchelnytskyi S; Hellman U; Filonenko V; Jungbluth AA; Odunsi K; Lloyd KO; Old LJ; Ritter G
Cancer Immun; 2008 Feb; 8():3. PubMed ID: 18251464
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical evaluation of epithelial ovarian carcinomas identifies three different expression patterns of the MX35 antigen, NaPi2b.
Levan K; Mehryar M; Mateoiu C; Albertsson P; Bäck T; Sundfeldt K
BMC Cancer; 2017 May; 17(1):303. PubMed ID: 28464843
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical analysis of NaPi2b protein (MX35 antigen) expression and subcellular localization in human normal and cancer tissues.
Kiyamova R; Shyian M; Lyzogubov VV; Usenko VS; Gout T; Filonenko V
Exp Oncol; 2011 Sep; 33(3):157-61. PubMed ID: 21956469
[TBL] [Abstract][Full Text] [Related]
5. The study of phosphate transporter NAPI2B expression in different histological types of epithelial ovarian cancer.
Gryshkova V; Goncharuk I; Gurtovyy V; Khozhayenko Y; Nespryadko S; Vorobjova L; Usenko V; Gout I; Filonenko V; Kiyamova R
Exp Oncol; 2009 Mar; 31(1):37-42. PubMed ID: 19300415
[TBL] [Abstract][Full Text] [Related]
6. Rebmab200, a humanized monoclonal antibody targeting the sodium phosphate transporter NaPi2b displays strong immune mediated cytotoxicity against cancer: a novel reagent for targeted antibody therapy of cancer.
Lopes dos Santos M; Yeda FP; Tsuruta LR; Horta BB; Pimenta AA; Degaki TL; Soares IC; Tuma MC; Okamoto OK; Alves VA; Old LJ; Ritter G; Moro AM
PLoS One; 2013; 8(7):e70332. PubMed ID: 23936189
[TBL] [Abstract][Full Text] [Related]
7. Generation of monoclonal antibodies against tumor-associated antigen MX35/sodium-dependent phosphate transporter NaPi2b.
Gryshkova V; Lituiev D; Savinska L; Ovcharenko G; Gout I; Filonenko V; Kiyamova R
Hybridoma (Larchmt); 2011 Feb; 30(1):37-42. PubMed ID: 21466284
[TBL] [Abstract][Full Text] [Related]
8. Binding Affinity, Specificity and Comparative Biodistribution of the Parental Murine Monoclonal Antibody MX35 (Anti-NaPi2b) and Its Humanized Version Rebmab200.
Lindegren S; Andrade LN; Bäck T; Machado CM; Horta BB; Buchpiguel C; Moro AM; Okamoto OK; Jacobsson L; Cederkrantz E; Washiyama K; Aneheim E; Palm S; Jensen H; Tuma MC; Chammas R; Hultborn R; Albertsson P
PLoS One; 2015; 10(5):e0126298. PubMed ID: 25970341
[TBL] [Abstract][Full Text] [Related]
9. Development of monoclonal antibodies specific for the human sodium-dependent phosphate co-transporter NaPi2b.
Kiyamova R; Gryshkova V; Ovcharenko G; Lituyev D; Malyuchik S; Usenko V; Khozhayenko Y; Gurtovyy V; Yin B; Ritter G; Old L; Filonenko V; Gout I
Hybridoma (Larchmt); 2008 Aug; 27(4):277-84. PubMed ID: 18724815
[TBL] [Abstract][Full Text] [Related]
10. NaPi2b expression in a large surgical Non-Small Cell Lung Cancer (NSCLC) cohort.
Heynemann S; Yu H; Churilov L; Rivalland G; Asadi K; Mosher R; Hirsch F; Rivard C; Mitchell P
Clin Lung Cancer; 2022 Mar; 23(2):e90-e98. PubMed ID: 34953676
[TBL] [Abstract][Full Text] [Related]
11. Toward a Topology-Based Therapeutic Design of Membrane Proteins: Validation of NaPi2b Topology in Live Ovarian Cancer Cells.
Bulatova L; Savenkova D; Nurgalieva A; Reshetnikova D; Timonina A; Skripova V; Bogdanov M; Kiyamova R
Front Mol Biosci; 2022; 9():895911. PubMed ID: 35911971
[TBL] [Abstract][Full Text] [Related]
12. Preclinical Development of an Anti-NaPi2b (SLC34A2) Antibody-Drug Conjugate as a Therapeutic for Non-Small Cell Lung and Ovarian Cancers.
Lin K; Rubinfeld B; Zhang C; Firestein R; Harstad E; Roth L; Tsai SP; Schutten M; Xu K; Hristopoulos M; Polakis P
Clin Cancer Res; 2015 Nov; 21(22):5139-50. PubMed ID: 26156394
[TBL] [Abstract][Full Text] [Related]
13. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.
McCluggage WG
Pathology; 2011 Aug; 43(5):420-32. PubMed ID: 21716157
[TBL] [Abstract][Full Text] [Related]
14. [Expression of folate receptor alpha in ovarian epithelial tumors].
Shen DH; Xie JL; Zhang YL; Wang Y
Zhonghua Bing Li Xue Za Zhi; 2010 Nov; 39(11):747-51. PubMed ID: 21215165
[TBL] [Abstract][Full Text] [Related]
15. Clear cell carcinoma has an expression pattern of cell cycle regulatory molecules that is unique among ovarian adenocarcinomas.
Shimizu M; Nikaido T; Toki T; Shiozawa T; Fujii S
Cancer; 1999 Feb; 85(3):669-77. PubMed ID: 10091740
[TBL] [Abstract][Full Text] [Related]
16. Significant relationship between the LAT1 expression pattern and chemoresistance in ovarian clear cell carcinoma.
Sato K; Miyamoto M; Takano M; Furuya K; Tsuda H
Virchows Arch; 2019 Jun; 474(6):701-710. PubMed ID: 30637450
[TBL] [Abstract][Full Text] [Related]
17. Targeting NaPi2b in ovarian cancer.
Banerjee S; Drapkin R; Richardson DL; Birrer M
Cancer Treat Rev; 2023 Jan; 112():102489. PubMed ID: 36446254
[TBL] [Abstract][Full Text] [Related]
18. The ARID1A, p53 and ß-Catenin statuses are strong prognosticators in clear cell and endometrioid carcinoma of the ovary and the endometrium.
Heckl M; Schmoeckel E; Hertlein L; Rottmann M; Jeschke U; Mayr D
PLoS One; 2018; 13(2):e0192881. PubMed ID: 29451900
[TBL] [Abstract][Full Text] [Related]
19. Sodium-dependent phosphate transporter NaPi2b as a potential predictive marker for targeted therapy of ovarian cancer.
Nurgalieva AK; Popov VE; Skripova VS; Bulatova LF; Savenkova DV; Vlasenkova RA; Safina SZ; Shakirova EZ; Filonenko VV; Bogdanov MV; Kiyamova RG
Biochem Biophys Rep; 2021 Dec; 28():101104. PubMed ID: 34504954
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
